Skip to main content
Toggle navigation
Login
Search
Home
Conference Program
Poster Schedule
Home
Poster Schedule
All Days
Fri, Apr 5
Sat, Apr 6
Poster Schedule
Type here to filter the list
Friday, April 5, 2024
9:45 AM – 1:15 PM
(1) Nicotine Use and Patient Directed Discharge Rate in Psychiatric Inpatients
Favorite
9:45 AM – 1:15 PM
(2) Addressing the Whole Patient: Examination of Smoking Policies in SUD Treatment Facilities
Favorite
9:45 AM – 1:15 PM
(3) Substance Use Treatment Utilization Among Community-Supervised Individuals at Risk for HIV
Favorite
9:45 AM – 1:15 PM
(4) Unveiling Predictors and Impact: Harm Reduction Vending Machines in Clark County, NV
Favorite
9:45 AM – 1:15 PM
(5) Models for Accessing Harm Reduction Vending Machines: An Interrupted Time Series Design
Favorite
9:45 AM – 1:15 PM
(6) Racial Disparities in MOUD Initiation Among Medicaid Patients with Infective Endocarditis
Favorite
9:45 AM – 1:15 PM
(7) Outcomes of an Inpatient Microinduction Cross Taper Protocol, Results After 700+ Attempts
Favorite
9:45 AM – 1:15 PM
(8) Breastfeeding in Postpartum Patients with Opioid Use Disorder
Favorite
9:45 AM – 1:15 PM
(9) AnyTime, AnyWhere: Examining Low-Barrier Buprenorphine for Post Incarcerated Individuals
Favorite
9:45 AM – 1:15 PM
(10) Exploring Unintended Pregnancy Among Patients with Opioid Use Disorder
Favorite
9:45 AM – 1:15 PM
(11) Associations between Gender and Prevalence of Daily Cannabis Use from 2008-2019
Favorite
9:45 AM – 1:15 PM
(12) Insurance and Racial/Ethnic Disparities in Receipt of Medications for Alcohol Use Disorder
Favorite
9:45 AM – 1:15 PM
(13) Contraceptive Uptake in Postpartum People with and without Opioid Use Disorder
Favorite
9:45 AM – 1:15 PM
(14) Comorbid Substance Use Disorders in Individuals with Diagnosed Eating Disorders
Favorite
9:45 AM – 1:15 PM
(15) Characterization of Young Adults Accessing Buprenorphine Telehealth in Philadelphia, PA
Favorite
9:45 AM – 1:15 PM
(16) ASAM Criteria-based Standardized Recommendations and Discrepancies with Actual Referrals
Favorite
9:45 AM – 1:15 PM
(17) Keeping Patients in Care?: Factors Associated with Patients Returning to Care
Favorite
9:45 AM – 1:15 PM
(18) Transition from Sublingual to LA Injectable Buprenorphine Best Practices
Favorite
9:45 AM – 1:15 PM
(19) Dosing to effect with Subcutaneous and Sublingual Buprenorphine for Opioid Use Disorder
Favorite
9:45 AM – 1:15 PM
(20) Low-Dose Buprenorphine Induction Protocols for Co-Occurring Pain and Opioid Use Disorders
Favorite
9:45 AM – 1:15 PM
(21) State Office-based Buprenorphine Treatment Laws: Counseling, Dosage, and Visit Frequency
Favorite
9:45 AM – 1:15 PM
(22) Effect of Buprenorphine/Naloxone and Methadone on Methamphetamine/Amphetamine Use
Favorite
9:45 AM – 1:15 PM
(23) The Impact of Mandatory Buprenorphine Training for Emergency Medicine Residents
Favorite
9:45 AM – 1:15 PM
(24) Naloxone Use and Knowledge from Patients Treated for Opioid Use Disorder
Favorite
9:45 AM – 1:15 PM
(25) Patient Experiences with Telehealth Treatment for Opioid Use Disorder in Alabama
Favorite
9:45 AM – 1:15 PM
(26) Overdose after Medication for Opioid Use Disorder Initiation Following Hospitalization
Favorite
9:45 AM – 1:15 PM
(27) Pilot Study Comparing Traditional to Low-Dose Initiation with Buprenorphine
Favorite
9:45 AM – 1:15 PM
(28) Neurocognitive Disorder and Exposure to Medication for Opioid Use Disorder
Favorite
9:45 AM – 1:15 PM
(29) Prioritizing Integration of Prescription Drug Monitoring Program into the EHR
Favorite
9:45 AM – 1:15 PM
(30) A Medications for Addiction Treatment (MAT) Release Program in the CDOC
Favorite
9:45 AM – 1:15 PM
(31) Increasing Dual Nicotine Replacement Prescribing within a Large Integrated Health System
Favorite
9:45 AM – 1:15 PM
(32) Enhancing Clinical Decision Support for Low-Threshold MAUD Prescribing in Primary Care
Favorite
9:45 AM – 1:15 PM
(33) Integration of Long-acting Injectable PrEP with MAT: A Pre-implementation Study
Favorite
9:45 AM – 1:15 PM
(34) Impact of Telehealth on Visit Attendance for Women with Opioid Use Disorder
Favorite
9:45 AM – 1:15 PM
(35) Consent First: Reviewing A Urine Drug Screening Protocol on Labor and Delivery
Favorite
9:45 AM – 1:15 PM
(36) Impact of Addiction Consult Social Workers on Hospital Readmission Rates
Favorite
9:45 AM – 1:15 PM
(37) Administration and Prescribing of Medications for Alcohol Use Disorder During COVID-19
Favorite
9:45 AM – 1:15 PM
(38) Getting Well: Expanding Tools to Treat Opioid Use Disorder In the Hospital
Favorite
9:45 AM – 1:15 PM
(39) Linking Hospitalized People with OUD to Treatment: Findings from a Multisite RCT
Favorite
9:45 AM – 1:15 PM
(40) Pilot Trial of a Digital Health Intervention for Opioid Use Disorder
Favorite
9:45 AM – 1:15 PM
(41) Xylazine Test Strip Performance in Synthetic and Human Urine Biospecimens
Favorite
9:45 AM – 1:15 PM
(42) Characterization of Patient-Directed Discharge in Patients with Substance Use Disorder(s)
Favorite
9:45 AM – 1:15 PM
(43) Improving Linkage to Addiction Treatment with Extended-release Naltrexone
Favorite
9:45 AM – 1:15 PM
(44) Non-Clinical Barriers and Facilitators to Treatment for Youth Who Use Opioids
Favorite
9:45 AM – 1:15 PM
(45) Urine Drug Screening in a Telehealth Setting for Opioid Use Disorder Treatment
Favorite
9:45 AM – 1:15 PM
(46) Rapid Conversion of High Dose Methadone to Buprenorphine Due to Persistent Hypoglycemia
Favorite
9:45 AM – 1:15 PM
(47) ''Gas Station Heroin'': Tianeptine, a Unique Tricyclic Antidepressant
Favorite
9:45 AM – 1:15 PM
(48) Opportunities for Harm Reduction: Multi-domain Needs Assessment of Unhoused Individuals
Favorite
9:45 AM – 1:15 PM
(49) Using Interpretable Machine Learning to Predict Access to Buprenorphine in Pharmacies
Favorite
9:45 AM – 1:15 PM
(50) Reduced Robo-Readmissions: Buprenorphine For Dextromethorphan Use Disorder
Favorite
9:45 AM – 1:15 PM
(51) Extended-Release Injectable Buprenorphine For Same-Day Induction – A Case Series
Favorite
9:45 AM – 1:15 PM
(52) Accelerated Inpatient Transition from Methadone to Long-Acting Injectable Buprenorphine
Favorite
9:45 AM – 1:15 PM
(53) Rapid Low-Dose – High-Dose Buprenorphine Initiation Using PO Methodology - Case Series
Favorite
9:45 AM – 1:15 PM
(54) High Dose Buprenorphine Induction Precipitating Non-Cardiogenic Pulmonary Edema
Favorite
9:45 AM – 1:15 PM
(55) Fentanyl to Buprenorphine < 24 Hours - Rapid Microinduction Buprenorphine Initiation
Favorite
9:45 AM – 1:15 PM
(56) Nonpharmacologic Interventions Ameliorate Withdrawal Signs in Opioid-Dependent Adults
Favorite
